pharminent

• Commercial

Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies

pharminent April 29, 2026

• M&A / Deals

Arcera and Fosun sign MoU for neuroscience innovation

pharminent April 29, 2026

• M&A / Deals

Rocket to sell PRV for $180m to advance gene therapy pipeline

pharminent April 29, 2026

• Commercial

Pfizer deals extend patent life for a top-selling rare disease drug

pharminent April 28, 2026

• Regulatory

Intellia Initiates Rolling BLA Submission for In Vivo CRISPR Therapy in Hereditary Angioedema

pharminent April 28, 2026

• M&A / Deals

AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B

pharminent April 28, 2026

• Clinical Data

Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3

pharminent April 28, 2026

• Clinical Data

AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer

pharminent April 28, 2026

• M&A / Deals

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

pharminent April 28, 2026

• M&A / Deals

Coultreon banks $125M to support testing of former Galapagos immune drug

pharminent April 28, 2026

• Regulatory

GSK eyes October FDA verdict on chronic hep B drug

pharminent April 28, 2026

• M&A / Deals

Merck KGaA and Remepy join forces to develop combo drug-digital therapies

pharminent April 28, 2026

• Commercial

Novartis shares fall as Entresto sales weaken

pharminent April 28, 2026

• Other

Seaport and Hemab target $180m IPOs as biotech listings accumulate

pharminent April 28, 2026

• Clinical Data

Boehringer/Zealand dual-acting drug causes 16.6% weight loss

pharminent April 28, 2026

• M&A / Deals

BioMarin acquires Amicus Therapeutics for $4.8bn

pharminent April 28, 2026

• Regulatory

FDA approves AstraZeneca’s Saphnelo for SLE

pharminent April 28, 2026

• Clinical Data

Oruka surges as long-acting psoriasis drug shows early promise

pharminent April 27, 2026

• Regulatory

Jazz Pharmaceuticals receives FDA Priority Review for Ziihera combo in first-line HER2+ GEA

pharminent April 27, 2026

• Other

GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio

pharminent April 27, 2026

• Pipeline

Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases

pharminent April 27, 2026

• Policy / Pricing

J&J puts blockbuster blood thinner Xarelto on TrumpRx

pharminent April 27, 2026

• M&A / Deals

Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis

pharminent April 27, 2026

• Regulatory

Novartis secures pair of regulatory wins for skin disease and malaria treatments

pharminent April 27, 2026

• Other

New NIHR-funded TRC for Parkinson’s disease

pharminent April 27, 2026

• Commercial

Lilly falls on slower start for Foundayo versus Wegovy

pharminent April 27, 2026

• Other

UK biotech could be bound for recovery, BIA report reveals

pharminent April 27, 2026

• Regulatory

UK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention

pharminent April 27, 2026

• M&A / Deals

Sun Pharma to acquire Organon for $11.75bn

pharminent April 27, 2026

• M&A / Deals

Sun sets out $11.75bn takeover play for Organon

pharminent April 27, 2026

• Gene Therapy

Gene therapy leaders aim to help more Baby KJs with novel regulatory models

pharminent April 27, 2026

• Regulatory

Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings

pharminent April 24, 2026

• Commercial

Daiichi Sankyo shares slip after delaying annual earnings report

pharminent April 24, 2026

• Pipeline

Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer

pharminent April 24, 2026

• M&A / Deals

Avalyn seeks public debut to support new lung drug formulations

pharminent April 24, 2026

• Commercial

Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels

pharminent April 24, 2026

• M&A / Deals

OZMOSI and Planview partner to enhance pharmaceutical data integration

pharminent April 24, 2026

• Clinical Data

Cardiometabolic trials: Using expertise to turn complexity into robust results

pharminent April 24, 2026

• Policy / Pricing

Regeneron cuts White House pricing deal, offers new gene therapy for free

pharminent April 24, 2026

• M&A / Deals

Cumberland to sell drug portfolio to Apotex for $100m

pharminent April 24, 2026